MedPath

WHO Announces New Treatment Regimens for Drug-Resistant Tuberculosis

The World Health Organization has released a rapid communication detailing upcoming updates to the treatment of drug-resistant tuberculosis, including new 6-month and 9-month regimens.

A rapid communication from the World Health Organization (WHO) Global Tuberculosis Programme has unveiled significant updates to the treatment guidelines for drug-resistant tuberculosis (DR-TB). These updates introduce a new 6-month regimen that combines bedaquiline (B), delamanid (D), and linezolid (L) with either levofloxacin (Lfx) or clofazimine (C), or both. Additionally, a set of 9-month regimens has been outlined for treating patients with MDR/RR-TB who do not exhibit fluoroquinolone resistance. This announcement precedes the release of updated WHO consolidated guidelines anticipated in early 2025, aiming to facilitate swift adaptation and planning by national TB programmes and stakeholders.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

New 4-Month TB Treatment Regimen Shows Effectiveness Comparable to Standard 6-Month Regimen

A new 4-month tuberculosis (TB) treatment regimen, involving high-dose daily rifapentine with moxifloxacin, isoniazid, and pyrazinamide, has been found to be as effective as the standard 6-month regimen for curing drug-susceptible TB disease. This regimen is recommended for individuals aged 12 and older with a body weight of at least 40 kg, who have pulmonary TB caused by organisms not known or suspected to be drug-resistant, and who have no contraindications to this regimen.

Levofloxacin Shows Promise in Preventing Multidrug-Resistant TB in Children

A clinical trial in South Africa demonstrated that a six-month, once-daily course of levofloxacin significantly reduces the risk of multidrug-resistant tuberculosis (MDR-TB) contraction in children.

Levofloxacin Shows Promise in Preventing Drug-Resistant TB in Household Contacts

A meta-analysis of two trials reveals that levofloxacin preventive treatment is associated with a 60% relative reduction in TB incidence among adults and children.

Quabodepistat Combination Shows Promise for Tuberculosis Treatment

A recent study published in _The Lancet Infectious Diseases_ explores the safety and efficacy of quabodepistat in combination with delamanid and bedaquiline for treating pulmonary tuberculosis.

FDA Updates Fludarabine Phosphate Labeling for CLL Treatment

The FDA has updated the labeling for fludarabine phosphate, expanding its approved use in treating B-cell chronic lymphocytic leukemia (CLL).

2025 GOLD COPD Guidelines Update: Dupilumab and Ensifentrine Included in Follow-Up Therapy

The 2025 GOLD report emphasizes precision medicine, incorporating a refined understanding of COPD pathophysiology for tailored treatment approaches.

Shorter, Tailored Regimen Shows Promise for Multi-Drug Resistant Tuberculosis

A new study suggests a six-to-nine-month regimen of bedaquiline, clofazimine, delamanid, and linezolid (BCDL) is effective for less severe MDR-TB, showing nearly 95% success.

Shorter Bedaquiline Regimens Show Sustained Efficacy Against Rifampicin-Resistant TB

A phase 3 trial follow-up reveals that bedaquiline-containing regimens for rifampicin-resistant tuberculosis (TB) maintain superiority over a 9-month injectable-based regimen at 132 weeks.

Atezolizumab, Venetoclax, and Obinutuzumab Show Promise in Richter Transformation DLBCL

A phase II trial (MOLTO) demonstrated that atezolizumab, venetoclax, and obinutuzumab achieved a 67.9% objective response rate in patients with Richter transformation diffuse large B-cell lymphoma (DLBCL-RT).

India Approves Shorter, More Effective BPaLM Regimen for Drug-Resistant TB

India's Health Ministry has approved the BPaLM regimen for Multi-Drug-Resistant Tuberculosis (MDR-TB) treatment, offering a shorter, more effective option.

Reference News

[1]
Key updates to the treatment of drug-resistant tuberculosis
who.int · Aug 19, 2024

WHO announces updates for DR-TB treatment, including a 6-month regimen with bedaquiline, delamanid, linezolid, and eithe...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy